PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2010-04-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 504
- Registration Number
- NCT00285012
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus
Phase 3
Terminated
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: Inhaled Insulin (Exubera)Other: Standard of Care
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 354
- Registration Number
- NCT00282971
- Locations
- 🇨🇦
Gain Medical Center, Coquitlam, British Columbia, Canada
🇨🇦Orillia Soldier's Memorial Hospital, Orillia, Ontario, Canada
🇨🇦Maritime Research Center, Bathurst, New Brunswick, Canada
A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT00282919
- Locations
- 🇮🇳
Pfizer Investigational Site, Bambolim, Goa, India
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 714
- Registration Number
- NCT00282984
- Locations
- 🇬🇧
Pfizer Investigational Site, Paisley, United Kingdom
Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone
Not Applicable
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00282945
- Locations
- 🇮🇱
Pfizer Investigational Site, Jerusalem, Israel
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Phase 2
Completed
- Conditions
- Kidney NeoplasmsCarcinoma, Renal Cell
- Interventions
- Drug: AG-013736 (axitinib)
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 62
- Registration Number
- NCT00282048
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.
Not Applicable
Terminated
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00280085
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9779
- Registration Number
- NCT00279448
- Locations
- 🇫🇷
Pfizer Investigational Site, Vannes, France
Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT00277810
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 113
- Registration Number
- NCT00277238
- Locations
- 🇺🇸
Pfizer Investigational Site, Richmond, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath